US Patent

US11717504 — Methods of reducing the risk of cardiovascular events in a subject

Method of Use · Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2030-04-29 · 4y remaining

Vulnerability score 59/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of reducing the risk of cardiovascular events in a subject on statin therapy by administering eicosapentaenoic acid ethyl ester or a derivative.

USPTO Abstract

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Drugs covered by this patent

Vascepa (ICOSAPENT ETHYL) · Amarin Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3669`	—	Vascepa
`U-3669`	—	Vascepa

Patent Metadata

Patent number: US11717504
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-29
Drug substance claim: No
Drug product claim: No
Assignee: Amarin Pharmaceuticals Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.